• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan

    3/25/25 1:11:06 PM ET
    $JNJ
    $TVGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $JNJ alert in real time by email

    David E Banko

    WARREN, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven immunotherapy drug discovery, today announced the appointment of David E. Banko, CPA, a leading expert with three decades of industry experience in market access and health policy, to its leadership team as Global Head of Government Affairs and Patient Access.

    In this critical role, Mr. Banko will spearhead market access strategies in collaboration with R&D across Tevogen's growing product portfolio in oncology, virology, neurology, and rheumatology to advance and support commercial readiness. His primary focus will be advancing patient access to the Company's therapies under development, engaging with government and private payers, and ensuring Health Technology Assessment (HTA) readiness. These initiatives are core to Tevogen's commercialization strategies, including securing appropriate coding, coverage, and provider reimbursement at launch. Mr. Banko will also lead policy engagement with the current administration to align on shared goals of improving patient accessibility and affordability of emerging medical innovations.

    Mr. Banko brings 30+ years of experience across pharma, medical devices, diagnostics, and hospital finance, with past roles at Cordis Corp, a former Johnson & Johnson (NYSE:JNJ) company, and B. Braun Medical Inc. An expert in securing and enhancing market access for innovative technologies, he has successfully leveraged clinical evidence to shape Medicare's national coverage policies, championed strategic global pricing, and developed initiatives that empower hospitals and physicians to advance the adoption of FDA-approved emerging breakthrough technologies.

    "David's appointment marks an important milestone in Tevogen's transition toward commercialization readiness," said Dr. Ryan Saadi, CEO and founder of Tevogen Bio. "Commercial success in today's healthcare environment requires not only scientific excellence but also clearly defined value propositions for patients, providers, payers, and policymakers alike. David's deep expertise in market access and health policy will be instrumental in ensuring our innovations are both accessible to patients and deliver lasting value across the healthcare ecosystem," he added.

    About Tevogen Bio

    Tevogen Bio is a clinical-stage specialty immunotherapy company harnessing one of nature's most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies to treat infectious disease and cancers, aiming to address the significant unmet needs of large patient populations. Tevogen Bio leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen Bio has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence.

    Tevogen Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen Bio's leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.

    Forward Looking Statements

    This press release contains certain forward-looking statements, including without limitation statements relating to: expectations regarding the healthcare and biopharmaceutical industries; Tevogen's development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer; Tevogen's plans to expand its efforts in artificial intelligence; Tevogen's ability to develop additional product candidates; Tevogen's use of funds from the grant; and the potential receipt of additional future grants. Forward-looking statements can sometimes be identified by words such as "may," "could," "would," "expect," "anticipate," "possible," "potential," "goal," "opportunity," "project," "believe," "future," and similar words and expressions or their opposites. These statements are based on management's expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company's control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.

    Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the outcome of any legal proceedings that may be instituted against Tevogen; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen's commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; the ability to develop, license or acquire new therapeutics; that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk of regulatory lawsuits or proceedings relating to Tevogen's business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen's limited operating history; and those factors discussed or incorporated by reference in Tevogen's Annual Report on Form 10-K and subsequent filings with the SEC.

    You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.

    Contacts

    Tevogen Bio Communications

    T: 1 877 TEVOGEN, Ext 701

    [email protected] 

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a855d43e-e0ad-4e29-b87b-cc5a0981aa66



    Primary Logo

    Get the next $JNJ alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $JNJ
    $TVGN

    CompanyDatePrice TargetRatingAnalyst
    Johnson & Johnson
    $JNJ
    5/13/2025$153.00Outperform → Market Perform
    Leerink Partners
    Tevogen Bio Holdings Inc.
    $TVGN
    3/4/2025$10.00Buy
    D. Boral Capital
    Johnson & Johnson
    $JNJ
    12/10/2024$166.00Neutral
    BofA Securities
    Johnson & Johnson
    $JNJ
    11/15/2024$190.00Outperform
    Wolfe Research
    Johnson & Johnson
    $JNJ
    7/23/2024$160.00 → $150.00Outperform → Neutral
    Daiwa Securities
    Johnson & Johnson
    $JNJ
    5/30/2024$160.00Neutral
    Goldman
    Johnson & Johnson
    $JNJ
    4/18/2024$170.00Hold → Buy
    HSBC Securities
    Johnson & Johnson
    $JNJ
    12/13/2023$170.00 → $163.00Overweight → Equal Weight
    Wells Fargo
    More analyst ratings

    $JNJ
    $TVGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tevogen CEO Contributes to Build-Out and First-Year Operations of New Headquarters

      Contribution highlights leadership's understanding of the importance AI will play in drug discovery WARREN, N.J., June 30, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced that founder and Chief Executive Officer, Ryan Saadi, M.D., M.P.H., has personally contributed $500,000 towards the build-out and first-year operating costs of Tevogen's new corporate headquarters in Warren, New Jersey. "This contribution is about belief in Tevogen's mission, in the remarkable people who bring that mission to life, and in the future we are building together," said Dr. Saadi. "Our purpose is more than a business plan; it is a shared promise to pat

      6/30/25 2:28:47 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AI Is Quietly Reinventing Healthcare--And Real Deployments Are Now Underway

      Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- Several experts are seeing that value of AI's total overhaul of healthcare, including beneficial additions such as generative AI apps demonstrating real value. The next wave of AI's healthcare transformation is already taking shape—led by intelligent agents, next-gen diagnostics, and predictive drug discovery platforms. Behind the scenes, a new class of innovators is making tangible progress, with companies like Avant Technologies, Inc. (OTCQB:AVAI), Tempus Ai, Inc. (NASDAQ:TEM), OmniAb, Inc. (NASDAQ:OABI), Tevogen Bio Holdings Inc. (NASDAQ:TVGN), and Recursion Pharmaceutic

      6/30/25 9:50:00 AM ET
      $OABI
      $RXRX
      $TEM
      $TVGN
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Computer Software: Programming Data Processing
    • Vicarious Surgical Announces Election of New Directors

      Vicarious Surgical Inc. (NYSE:RBOT, RBOT WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the election of Fuad Ahmad and Joseph Doherty to the Vicarious Surgical Board of Directors at the Company's 2025 Annual Meeting of Stockholders held on June 27, 2025. The Company also announced the departure of Ric Fulop from the Vicarious Surgical Board of Directors effective as of the Annual Meeting. "On behalf of the board, I am thrilled to welcome Fuad and Joseph to the Vicarious team. Their decades of experience and insight will be instrumental as we continue our advance towards our clinical trial and th

      6/30/25 6:45:00 AM ET
      $GSAT
      $IRIX
      $JNJ
      $MITK
      Telecommunications Equipment
      Consumer Discretionary
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $JNJ
    $TVGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Weinberger Mark A bought $147,220 worth of shares (1,000 units at $147.22) (SEC Form 4)

      4 - JOHNSON & JOHNSON (0000200406) (Issuer)

      12/12/24 5:27:36 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Desai Kirti bought $2,460 worth of shares (3,000 units at $0.82), increasing direct ownership by 0.03% to 9,699,186 units (SEC Form 4)

      4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

      6/13/24 4:30:24 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Saadi Ryan H. bought $2,000 worth of shares (2,607 units at $0.77), increasing direct ownership by 0.00% to 118,252,659 units (SEC Form 4)

      4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

      6/7/24 4:29:51 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $JNJ
    $TVGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Saadi Ryan H. was granted 8,000,000 shares, increasing direct ownership by 7% to 124,814,453 units (SEC Form 4)

      4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

      7/1/25 4:49:36 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Commercial Officer Khan Sadiq was granted 200,000 shares, increasing direct ownership by 21% to 1,169,618 units (SEC Form 4)

      4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

      7/1/25 4:49:18 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Desai Kirti was granted 750,000 shares, increasing direct ownership by 8% to 10,449,186 units (SEC Form 4)

      4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

      7/1/25 4:48:42 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $JNJ
    $TVGN
    SEC Filings

    See more
    • Tevogen Bio Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Tevogen Bio Holdings Inc. (0001860871) (Filer)

      7/3/25 5:25:45 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B5 filed by Tevogen Bio Holdings Inc.

      424B5 - Tevogen Bio Holdings Inc. (0001860871) (Filer)

      7/3/25 5:23:03 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tevogen Bio Holdings Inc. filed SEC Form 8-K: Other Events

      8-K - Tevogen Bio Holdings Inc. (0001860871) (Filer)

      6/30/25 5:21:55 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $JNJ
    $TVGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Tevogen Bio Holdings Inc.

      SC 13G/A - Tevogen Bio Holdings Inc. (0001860871) (Subject)

      11/14/24 5:29:01 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tevogen Bio Holdings Inc.

      SC 13G/A - Tevogen Bio Holdings Inc. (0001860871) (Subject)

      11/12/24 4:28:55 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Johnson & Johnson

      SC 13G - JOHNSON & JOHNSON (0000200406) (Filed by)

      4/10/24 5:12:55 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    $TVGN
    Financials

    Live finance-specific insights

    See more
    • Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

      Johnson & Johnson (NYSE:JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 16th to review second-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson's executive team. Investors and other interested parties can access the webcast/conference call in the following ways: The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay o

      5/28/25 4:43:00 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Johnson & Johnson Announces 63rd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.8%

      Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a 4.8% increase in the quarterly dividend, from $1.24 per share to $1.30 per share, marking the 63rd year of consecutive increases. At the new rate, the indicated dividend on an annual basis is $5.20 per share compared to the previous rate of $4.96 per share. The next quarterly dividend is payable on June 10, 2025 to shareholders of record at the close of business on May 27, 2025. The ex-dividend date is May 27, 2025. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, trea

      4/15/25 6:25:00 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Johnson & Johnson Reports Q1 2025 Results

      2025 First-Quarter reported sales growth of 2.4% to $21.9 Billion with operational growth of 4.2%* and adjusted operational growth of 3.3%* 2025 First-Quarter earnings per share (EPS) increased to $4.54 which includes the reversal of special charges and adjusted EPS increased to $2.77 or 2.2%* Significant new product pipeline progress including approval of TREMFYA in Crohn's disease, data for RYBREVANT/LAZCLUZE overall survival in non-small cell lung cancer and icotrokinra in plaque psoriasis, and initiation of the clinical trial for a general surgery robotic system, OTTAVA Company increases Full-Year 2025 operational sales2,5 guidance to reflect the addition of CAPLYTA following the

      4/15/25 6:20:00 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    $TVGN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • July 21, 2023 - FDA Roundup: July 21, 2023

      For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin

      7/21/23 4:02:23 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

      For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not

      5/5/22 4:51:11 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

      For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione

      8/18/21 1:06:11 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    $TVGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Johnson & Johnson downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Johnson & Johnson from Outperform to Market Perform and set a new price target of $153.00

      5/13/25 8:56:13 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • D. Boral Capital initiated coverage on Tevogen Bio with a new price target

      D. Boral Capital initiated coverage of Tevogen Bio with a rating of Buy and set a new price target of $10.00

      3/4/25 8:26:08 AM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BofA Securities resumed coverage on Johnson & Johnson with a new price target

      BofA Securities resumed coverage of Johnson & Johnson with a rating of Neutral and set a new price target of $166.00

      12/10/24 8:28:42 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    $TVGN
    Leadership Updates

    Live Leadership Updates

    See more
    • Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors

      Johnson & Johnson (NYSE:JNJ) announced today that Daniel Pinto, President, JPMorganChase, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250610707025/en/ "We are thrilled to have Daniel join Johnson & Johnson's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is an exceptional leader with deep financial expertise and understanding of global capital markets. Daniel's unique perspective and wealth of experience will be a tremendous asset to Johnson & Johnson as we continue to invest in and advance the next generation of healthcare inno

      6/10/25 4:51:00 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald

      WARREN, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today reminds that CEO Dr. Ryan Saadi MD, MPH will participate in BioNJ's Fifteenth Annual Bio Partnering Conference. Dr. Saadi will be featured on the panel discussion titled Paths to Liquidity: Strategies for Adapting to a Volatile Market, moderated by David C Schwartz, Partner at Morgan Lewis. Along with Dr. Ryan Saadi, the panel will also include commentary from Matt Vamvakis, MBA, Managing Director, J.P. Morgan Private Bank, Amanda Laskey, Life Sciences Senior Analyst, RSM US, and Kee Colon, MBA, Managing Director, Cantor Fitzgerald. The conference, held on May 13, 2025,

      4/29/25 8:00:00 AM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald

      WARREN, N.J., April 14, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announces CEO Dr. Ryan Saadi, MD, MPH, will participate in BioNJ's Fifteenth Annual Bio Partnering Conference. Dr. Saadi will be featured on the panel discussion titled Paths to Liquidity: Strategies for Adapting to a Volatile Market, moderated by David C Schwartz, Partner at Morgan Lewis. Along with Dr. Ryan Saadi, the panel will also include commentary from Matt Vamvakis, MBA, Managing Director, J.P. Morgan Private Bank, Amanda Laskey, Life Sciences Senior Analyst, RSM US, and Kee Colon, MBA, Managing Director, Cantor Fitzgerald. The conference, held on May 13, 2025,

      4/14/25 1:53:50 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care